Advances in clinical trials for amyotrophic lateral sclerosis.

Author(s): Gordon PH

Affiliation(s): Eleanor and Lou Gehrig MDA/ALS Research Center, Neurological Institute, 9th Floor, 710 West 168th Street, New York, NY 10032, USA. Phg8@columbia.edu

Publication date & source: 2005-02, Curr Neurol Neurosci Rep., 5(1):48-54.

Publication type: Review

Because treatments are not yet powerful enough to reverse the symptoms of amyotrophic lateral sclerosis (ALS), randomized placebo-controlled trials remain the gold standard for testing new therapies. To date, only one drug, riluzole, has been shown to slow the course of ALS, albeit in a very modest way. Since the approval of riluzole almost 10 years ago, there have been a number of negative trials, and we still await the discovery of a medication with a truly meaningful effect. With each study, our sophistication in trial design grows, but hurdles remain, including how to use transgenic animal models optimally, which outcome measures most accurately reflect changes in the disease, and how to reduce the often high dropout rates in trials of ALS. This article is devoted to the recent evolution of clinical trials in ALS and discusses specific trials conducted during the past 5 years.